Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: OmarigliptinDrug: Matching placebo to omarigliptinDrug: Matching placebo to glimepirideDrug: GlimepirideDrug: Insulin glargineDrug: Metformin
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 402
- Registration Number
- NCT01755156
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
- Conditions
- Relapsed Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT01750567
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Prostate Cancer Active Surveillance Metformin Trial
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT01733836
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Effects of Metformin on Hepatic FFA Metabolism
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Lars Christian Gormsen
- Target Recruit Count
- 36
- Registration Number
- NCT01729156
Bioequivalence Study for Acarbose / Metformin FDC
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT01728740
A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT01729403
Interaction Between St John's Wort and Metformin?
- Conditions
- DepressionType 2 Diabetes
- Interventions
- Other: St John's WortDrug: Metformin
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 20
- Registration Number
- NCT01726764
- Locations
- 🇩🇰
Department of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 53
- Registration Number
- NCT01725126
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 34
- Registration Number
- NCT01725490
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT01720290
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.